Linked Life Data

12426512

Source:http://linkedlifedata.com/resource/pubmed/id/12426512

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2002-11-11
pubmed:abstractText
Celecoxib is a member of a novel group of agents that selectively inhibit cyclooxygenase 2 (COX-2). COX-2 inhibitors have emerged as an important class of drugs because of the lower incidence of side effects when compared with traditional nonsteroidal anti-inflammatory drugs, which inhibit both cyclooxygenase 1 and COX-2. Because children often differ from adults with respect to drug disposition, the objective of this study was to determine the single-dose and steady-state pharmacokinetics of celecoxib in pediatric patients.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0009-9236
pubmed:author
pubmed:issnType
Print
pubmed:volume
72
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
490-7
pubmed:dateRevised
2007-1-18
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Single-dose and steady-state pharmacokinetics of celecoxib in children.
pubmed:affiliation
New Agents and Innovative Therapy Program, Divisions of Hematology/Oncology and Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Ontario, Canada.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II, Clinical Trial, Phase I